文献速递淋巴瘤

序贯P-GEMOX联合放疗治疗早期结外NK/T细胞淋巴瘤的多中心研究

Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
PubMed 文献 · Am J Hematol · 2021-09-13

该多中心研究纳入202例早期结外NK/T细胞淋巴瘤患者,评估序贯P-GEMOX方案联合放疗的疗效与毒性。最佳总缓解率96.0%,完全缓解率83.2%,中位随访44.1个月,3年无进展生存率74.6%、总生存率85.2%,毒性可耐受。

要点

  • 序贯P-GEMOX联合放疗对早期ENKTL疗效良好且毒性可管理。
  • 广泛原发肿瘤和ECOG评分≥2是独立不良预后因素。
  • 列线图修订风险指数模型预后分层能力最优。

核心结论

  • 序贯P-GEMOX联合放疗疗效良好、毒性可接受,可作为早期ENKTL的有效治疗选择。

研究设计与样本

  • 多中心研究,纳入6个中心202例诊断为早期ENKTL的中国患者,接受序贯P-GEMOX联合放疗。

主要发现

  • 最佳总缓解率96.0%,168例(83.2%)达到完全缓解。
  • 中位随访44.1个月,3年无进展生存率74.6%,总生存率85.2%。
  • 多因素分析显示广泛原发肿瘤是无进展生存(HR 3.660,95%CI 1.820-7.359,p<0.001)和总生存(HR 3.825,95%CI 1.442-10.148,p=0.007)的独立预后因素。
  • ECOG评分≥2是无进展生存(HR 3.042,95%CI 1.468-6.306,p=0.003)和总生存(HR 3.983,95%CI 1.678-9.457,p=0.02)的独立预后因素。
  • 列线图修订风险指数模型预后分层能力最优(无进展生存p<0.001;总生存p<0.001),人群分布相对均衡。

临床怎么用

  • 对于早期ENKTL患者,可考虑序贯P-GEMOX联合放疗作为联合模式治疗选项。
  • 治疗前应评估原发肿瘤范围和ECOG评分以进行风险分层。
  • 可采用列线图修订风险指数模型辅助预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extranodal natural killer/T-cell lymphoma, nasal-type (ENKTL) is a distinct subtype of non-Hodgkin lymphoma and most of the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for patients with early-stage ENKTL. However, the optimal CMT has not been fully clarified. This study reports the efficacy and toxicity of sequential P-GEMOX (pegaspargase, gemcitabine and oxaliplatin) and radiotherapy in a large Chinese cohort comprising of 202 patients diagnosed with early-stage ENKTL from six medical centers. The observed best overall response rate was 96.0% and 168 (83.2%) patients achieved complete remission. With a median follow-up of 44.1 months, the 3-year progression-free survival (PFS) and overall survival (OS) were 74.6% and 85.2%, respectively. Multivariate analysis suggested that extensive primary tumor (PFS, hazard ratio [HR] 3.660, 95% CI 1.820-7.359, p < 0.001; OS, HR 3.825, 95% CI 1.442-10.148, p = 0.007) and Eastern Cooperative Oncology Group performance status ≥ 2 (PFS, 3.042, 95% CI 1.468-6.306, p = 0.003; OS, HR 3.983, 95% CI 1.678-9.457, p = 0.02) were independent prognostic factors for survival outcomes. Among the established prognostic models for ENKTL, the nomogram-revised risk index model had optimal prognostic risk stratification ability (PFS, p < 0.001; OS, p < 0.001) and relatively balanced population distribution. The adverse events of this CMT were well-tolerated and manageable. In conclusion, sequential P-GEMOX and radiotherapy showed favorable efficacy with acceptable toxicity, and could be an effective treatment option for early-stage ENKTL patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Ma S, Cai J, et al. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study. Am J Hematol. 2021. PMID: 34449095. doi:10.1002/ajh.26335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。